A Combination Therapy of JO-I and Chemotherapy in Ovarian Cancer Models
Abstract
The goal of this Translational Pilot Award proposal is to create the basis for a clinical trial for JO-1 in combination with chemotherapy in patients with progressive ovarian cancer. Toward this goal we will perform i) detailed safety studies in DSG2 transgenic mice, ii) study the effect of JO-1 in ovarian cancer models, and iii) test combinations of JO-1 with major chemotherapy drugs. We report the following progress: 1) A manufacturing protocol for JO-1 at large scale has been established. 2) There were no adverse effects after intravenous injection of JO-1 in DSG2 transgenic mice. 3) JO-1 has favorable pharmacokinetics parameters. 4) The effect of JO-1 on normal tissues is minimal because DSG2 is trapped in epithelial junctions in normal tissues and not accessible to intravenously injected JO-1. 5) JO-1 enhances Doxil chemotherapy in xenograft models of ovarian cancer and in mouse models with syngeneic tumors.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2013
- Accession Number
- ADA598401
Entities
People
- André Lieber
Organizations
- University of Washington